Sab Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.